Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

Microsatellite-stable (MSS) colorectal cancer (CRC) has shown poor response to checkpoint blockade immunotherapy. Here, the authors show that the combination of oxaliplatin with anti-PDL1 mAb is specifically efficient in the treatment of MSS CRC.

Guardado en:
Detalles Bibliográficos
Autores principales: Wantong Song, Limei Shen, Ying Wang, Qi Liu, Tyler J. Goodwin, Jingjing Li, Olekasandra Dorosheva, Tianzhou Liu, Rihe Liu, Leaf Huang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Q
Acceso en línea:https://doaj.org/article/0515a6d971844b1e8f9a10f726dac7a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!